country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-179613

Copy Link Print Information

D-Leucine amide-CDDO-Me-HMP

D-Leucine amide-CDDO-Me-HMP is a prodrug composed of CDDO-Me (HY-13324) and ligustrazine (HY-N0264). D-Leucine amide-CDDO-Me-HMP can protect against CCl₄-induced liver injury. D-Leucine amide-CDDO-Me-HMP can inhibit ROS production, alleviates mitochondrial damage and inhibits cell apoptosis. D-Leucine amide-CDDO-Me-HMP can be used for the research of liver injury.

For research use only. We do not sell to patients.

CAS No.: 2749600-16-4
Formula: C₅₃H₇₃N₅O₆
Molecular Weight:876.18

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

D-Leucine amide-CDDO-Me-HMP Chemical Structure

CAS No.: 2749600-16-4

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Heme Oxygenase (HO) Isoforms :

HO-1
HO-2

All Bcl-2 Family Isoforms :

All Caspase Isoforms :

In Vitro

D-Leucine amide-CDDO-Me-HMP (CHL) (0.05-0.10 μM, 24 h) significantly enhances cell viability in CCl₄-induced LO2 and RAW264.7 liver injury cell models^[1].
D-Leucine amide-CDDO-Me-HMP (0.05-0.10 μM, 24 h) reduces ROS levels, alleviates mitochondrial damage and inhibits cell apoptosis in CCl₄-induced LO2 and RAW264.7 liver injury cell models^[1].
D-Leucine amide-CDDO-Me-HMP (0.10 μM, 24 h) significantly upregulates the expression of Nrf2 and HO-1 proteins in CCl₄-induced LO2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

CCl₄ induced LO2 and RAW264.7 liver injury cells
Concentration:

0.05 and 0.10 μM
Incubation Time:

24 h
Result:

Showed cell viability of 98.4% in LO2 cells and 92.6% in RAW264.7 cells.

Immunofluorescence^[1]

Cell Line:

CCl₄ induced LO2 and RAW264.7 liver injury cells
Concentration:

0.05 and 0.10 μM
Incubation Time:

24 h
Result:

Reduced the fluorescence intensity of DCF.
Reduced the fluorescence intensity of J-monomer and Increased the fluorescence intensity of J-aggregate.

In Vivo

D-Leucine amide-CDDO-Me-HMP (CHL) (15-30 mg/kg, i.p., administered after CCl₄-induced liver injury) improves liver tissue morphology and pathological damage in C57BL/6 mouse liver injury models induced by CCl4^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (8 weeks of age, 18–20 g, CCl₄-induced liver injury)^[1]
Dosage:

15 mg/kg, 30 mg/kg
Administration:

Intraperitoneally injection
Result:

Reduced serum levels of ALT and AST.
Alleviated steatosis and inflammatory infiltration.
Upregulated the expression of HO-1 (4.2-fold) and NQO1 (5.5-fold) in liver tissue.
Downregulated the expression of p-p65 (5-fold) and pro-apoptotic protein BAX.
Upregulated the expression of anti-apoptotic protein Bcl-2, and inhibited excessive activation of Caspase-3.

Chemical Information

CAS No. 2749600-16-4
Molecular Weight 876.18
Formula C₅₃H₇₃N₅O₆
SMILES

[H][C@@]12CC(C)(CC[C@@]1(CC[C@]3([C@@]4(CC[C@]5(C(C)(C(OCC6=CC=C(C=C6)NC([C@@H](CC(C)C)N)=O)=C(C([C@@]5(C4=CC([C@]23[H])=O)C)OCC7=NC(C)=C(N=C7C)C)C#N)C)[H])C)C)C(OC)=O)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chen F, et al. Development of a leucine aminopeptidase-activatable co-prodrug from CDDO-Me and ligustrazine for synergistic treatment of liver injury. Bioorg Chem. 2025;166:109177. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

D-Leucine amide-CDDO-Me-HMP

All Heme Oxygenase (HO) Isoforms

All Bcl-2 Family Isoforms

All Caspase Isoforms